Treatment with an inhibitor of the epigenetic enzyme SETD8 may be a novel therapeutic option to overcome melphalan resistance in patients with multiple myeloma (MM), according to research published in Clinical Epigenetics. Most patients with MM eventually relapse or develop drug resistance despite treatment advances that have improved survival rates. SETD8,...
treatment News
DUARTE, Calif. – In a breakthrough for human milk science, researchers at City of Hope, Los Angeles, have dosed the first patient in a Phase 2a clinical trial evaluating a novel therapy for blood cancer patients undergoing allogeneic hematopoietic stem cell transplantation. The investigational treatment, PBCLN-010 in combination with PBCLN-014,...
Boca Raton, Florida — INmune Bio Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is pleased to share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for...
MARSEILLE, France – Innate Pharma SA today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the lacutamab IND. On October 5, Innate announced that the lacutamab IND has been placed on partial clinical hold by FDA following a recent patient death...
MARSEILLE, France – Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced the first patient was dosed in its Phase 1/2 multicenter trial, investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma (NHL). IPH6501 is Innate’s first-in-class CD20-targeting tetraspecific ANKET® (Antibody-based...
BEIJING, China — InnoCare Pharma, a commercial-stage biotech company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Company’s B-cell lymphoma-2 (BCL2) inhibitor, ICP-248. This is InnoCare’s fifth innovative drug to enter the clinical stage in the USA. This...
BEIJING, China — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare’s novel SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor, ICP-189, with ArriVent’s furmonertinib,...
BEIJING, China — InnoCare today announced that tafasitamab (Minjuvi®) in combination with lenalidomide has been recently approved by the Medical Products Administration of Guangdong Province, under the early access program in Guangdong-Hong Kong-Macao Greater Bay Area (“Greater Bay Area” for short), for the treatment of adult patients with relapsed or...
Tucson, Arizona – Mosquito-borne illnesses remain a formidable challenge threatening millions of people each year with diseases such as malaria, dengue, zika and chikungunya. To develop a mosquito control strategy with a minimal ecological footprint, biochemists and entomologists from the University of Arizona have pioneered a novel approach by harnessing...
LONDON, UK – Hyris Ltd, working with an international team of researchers, has developed a prototype field-deployable surveillance system to detect insecticide-resistant malaria vector mosquitoes in the field without the need for transportation to sophisticated laboratories. The prototype can diagnose a mosquito for insecticide resistance at the field site three...